Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer

Cancer Biology and Therapy

Volumn 5, Issue 5, 2006, Pages 505-510

  Roldán, Gloria ^a,b   Delgado, Lucía ^a   Musé, Ignacio Miguel ^a  

^a UNIVERSITY OF URUGUAY   (Uruguay)

^b TOM BAKER CANCER CENTRE   (Canada)

Author keywords

BRCA1; Estrogen receptor alpha; ID4; mRNA expression; Sporadic breast cancer

Indexed keywords

BRCA1 PROTEIN; ESTROGEN RECEPTOR ALPHA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HELIX LOOP HELIX PROTEIN; PROTEIN INHIBITOR OF DNA BINDING 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 33646796032     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.5.2597     Document Type: Article

References (50)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83:18-29.
2. Ferlay J, Parkin DM, Pisani P. GLOBOCAN: Cancer incidence and mortality worldwide. International Agency for Research on Cancer (IARC), Cancer Base 3. Lyon, France: IARC, 1998, (Online: http://www-dep.iarc.fr/). Consulted: 5/03/05).
3. Vassallo J, Barrios E, De Stefani E, Ronco A. II Atlas de Incidencia del cáncer en Uruguay 1996-1997. Montevideo: Comisión Honoraria de Lucha contra el Cáncer, 2001, (Online: http://www.urucan.org.uy. Consulted: 5/03/05).
4. Vasallo J, Barrios E. II Atlas de mortalidad por cáncer en el uruguay. Montevideo; Comisión Honoraria de Lucha contra el Cáncer 2001, (Online: http://www.urucan.org.uy. Consulted: 5/03/05).
5. Dickson R, Pestell R, Lippman M. Molecular biology of breast cancer. In: De Vita, Hellman, eds. Cancer Princyples and Practice of Oncology. 7th ed. Rosenberg: 2004, (CD-Room).
6. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier J, Birnbaum D, Sobol H. Germ Line Mutation at BRCA1 affects the Histoprognostic grade in Hereditary Breast Cancer. Cancer Res 1996; 56:471-4.
7. Arver B, Du Q, Chen J, Luo L, Lindblom A. Hereditary breast cancer: A review. Sem Cancer Biol 2000; 10:271-88.
8. Iau P, Macmillan R, Bramey R. Germ line mutations associated with breast cancer susceptibility. Eur J Cancer 2001; 37:300-321.
9. Yang Q, Sakurai T, Mori I, Yoshimura G, Nakamura M, Nakamura Y, Suzuma T, Tamaki T, Umemura T, Kakudo K. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 2001; 921:54-60.
10. Yoshikawa K, Honda K, Inamoto T, Shinohara H, Yamauchi A, Suga K, Okuyama T, Shimada T, Kodama H, Noguchi S, Gazdar AF, Yamaoka Y, Takahashi R. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 1999; 586:1249-61.
11. Yoshikawa K, Ogawa T, Baer R, Hemmi H, Honda K, Yamauchi A, Inamoto T, Ko K, Yazumi S, Motoda H, Kodama H, Noguchi S, Gazdar AF, Yamaoka Y, Takahashi R. Abnormal expression of BRCA1 and BRCA1-interactive DNA repair proteins in breast carcinomas. Int J Cancer 2000; 88:28-36.
12. Narod S, Foulkes W. BRCA1 and BRCA2: 1994 and beyond. Nature Rev Cancer 2004; 4:665-76.
13. Welcsh P, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001; 10:705-13.
14. Au WW, Henderson BR. The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci. J Biol Chem 2005; 280:6993-7001.
15. Wang Q, Zhang H, Fishel R, Greene MI. BRCA1 and cell signaling. Oncogene 2000; 19:6152-8.
16. Magdinier F, Billiar L, Wittmann G, Frappart L, Benchaib M, Lenoir G. Regional methylation of the 5′ end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells. FASEB J 2000; 14:1585-94.
17. Rice J, Ozcelik H, Maxeiner P, Andrulis I, Futscher B. Methylation of the BRCA1 promoter is associates with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000; 21:1761-5.
18. Rice J, Futscher B. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Ac Res 2000; 28:2133-9.
19. BC014941. Nucleotide. NCBI. Online. Actualized: 29/6/04. Consulted: 5/5/2005, (http://www.ncbi.nlmnih.gov/entrez/viewer.fcgi?db=Nucleotide&dopt= GenBank&vol=BC014941).
20. Aceview NCBI. Online. Actualized: 11/04; Consulted: 01/05, (http://www.ncbi.nih.gov/IEB/Research/Acembly/av.cgi?db=human&l=ID4).
21. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: A negative regulator of helix-loop-helix DNA binding proteins. Cell 1990; 61:49-59.
22. Massari M, Murre C. Helix-Loop-Helix Proteins: Regulators of transcription in eucaryotic organisms. Mol and Cell Biol 2000; 20:429-40.
23. Chaudhary J, Schmidt M, Sadler-Riggleman I. Negative acting HLH proteins Id1, Id2, Id3 and Id4 are expressed in prostate epithelial cells. Prostate 2005; 64:253-64.
24. Lasorrella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene 2001; 20:8326-33.
25. Zebedee Z, Hara E. Id proteins in cell cycle control and cellular senescence. Oncogene 2001; 20:8317-25.
26. Atchley WR, Fitch WM. A natural classification of the basic helix-loop-helix class of transcription factors. Proc Natl Acad Sci USA 1997; 94:5172-6.
27. Beger C, Pierce L, Krüger M, Marcusson E, Robbins J, Welcsh P, Welch PJ, Welte K, King MC, Barber JR, Wong-Staal F. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Nath Acad Sci 2001; 98:130-5.
28. Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, Warrington JA, King MC. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA 2002; 99:7560-5.
29. De Candia P, Benera R, Solit DB. A role for Id proteins in mammary gland physiology and tumorigenesis. Adv Cancer Res 2004; 92:81-94.
30. Perk J, Iavarone A, Benezra R. ID family of helix-loop-helix proteins in cancer. Nature 2005; 5:603-614, (www.nature.com/reviews/cancer).
31. Shan L, Yu M, Qiu C, Snyderwine EG. Id4 regulates mammary epithelial cell growth and differentiation and is overexpressed in rat mammary gland carcinomas. Am J Pathol 2003; 163:2495-202.
32. Umetani N, Takuji M, Koyanagi K, Shinozaki M, Kim J, Giuliano E, Hoon D. Aberrant hypermethilation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 2005; 24:4721-7.
33. Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 2000; 18:107s-12s.
34. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1-and BRCA2- related breast cancer. Semin Surg Oncol 2000; 18:287-95.
35. Vaurs-Barriere C, Vidal V, Penault-Llorca F, Kwiatkowski F, Maugard CY, Bignon Y. Pathology of sporadic breast tumors with LOH at BRCA1 locus: Correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability. Int J Oncol 1998; 12:1373-8.
36. Lynch B, Holden J, Buys S, Neuhausen S, Gaffney D. Pathobiologic characteristics of hereditary breast cancer. Human Pathol 1998; 29(10):1140-4.
37. Lakhani S, van de Vijver M, Jacquemier J, Anderson T, Osin P, McGuffog L. The Pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2 and p53 in patients with mutations in BRCA1 and BRCA2. JCO 2002; 20d:2310-8.
38. Amirrad M, Al-Mulla F, Varadharaj G, John B, Saji T, Anim J. BRCA1 gene expression in breast cancer in Kuwait: Correlation with prognostic parameters. Med Princ Pract 2005; 14:67-72.
39. Niwa Y, Oyama T, Nakajima T. BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Jpn J Cancer Res 2000; 91:519-26.
40. Jarvis E, Kirk J, Clarke C. Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet Cytogenet 1998; 101:109-15.
41. Egawa C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics. Jpn J Cancer Res 2001; 92:624-30.
42. Fan S, Ma Y, Wang C, Yuan R, Meng Q, Wang J, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM. p300 modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 2002; 62:141-51.
43. Chomczynski P, Sacchi N. Single-step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 163:156-9.
44. Dörk T, Skawran B, Stuhrmann M, Bremer M, Karstens J. BRCA1 expression is not affected by the intronic12 bp duplication. J Med Genet 1999; 36:262-3.
45. Fuqua S, Fallete N, McGuire W. Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. J Natl Cancer Inst 1990; 82:858-61.
46. Barnes D. Expression and function of BRCA1 and BRCA2 in familial and sporadic breast cancer. Histopathology 1999; 34:170-4.
47. Ozcelik H, To MD, Couture J, Bull SB, Andrulis IL. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Int J Cancer 1998; 77:1-6.
48. Artagaveytia N, Raymondo S, Román E, Delgado L, Alonso I, Alonso O, Leborgne F, Sabini G, Garófalo G. Receptores hormonales en el cáncer de mama y su relación con algunos parámetros de la enfermedad. Arch Med Int 1997; (suppl):50.
49. Skog S, He Q, Khoshonoud R, Fornander T, Rutqvist LE. Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line. Tumour Biol 2004; 25:41-7.
50. Sidoni A, Cavalieri A, Bellezza G, Scheibel M, Bucciarelli E. Breast cancer in young women. Clinico-pathological features and biological specificity. Breast 2003; 12:247-50.